ClinicalTrials.gg
CompletedNCT02847260RAPIDUpdated Oct 17, 2017Results posted

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

A Phase 4 interventional study of Remodulin in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-17.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
16th of 44
39 · median 32
Started
2012
with 4 others
Phase 4
14 of 44
1 open now
Registered
26th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 16th largest by enrollment, is one of 5 that started in 2012, is one of 14 in phase 4, and was the 26th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.

Read the detailed description

This is an open label, single territory, multi-centre study in subjects with pulmonary arterial.

hypertension (PAH). Subjects were treatment naïve or receiving an approved endothelin receptor antagonist (ERA) and / or phosphodiesterase (PDE)-5 inhibitor for at least 60 days prior to screening and maintained on a stable dose for at least 30 days.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is at least 18 years of age at screening.
  2. The subject weigh a minimum of 40 kg with a less than 40 kg/m\^2 at screening.
  3. Sexually active women of must use two different forms of highly effective . Males participating in the study must use a condom during the length of the study, and for at least 64 days after discontinuing study drug.
  4. The subject has a diagnosis of symptomatic idiopathic or heritable PAH (IPAH or HPAH).
  5. A Baseline 6MWD between 150 and 550 metres is required, in the absence of a concurrent injury, illness (other than PAH or a PAH related condition), or other confounding factors that would effect the subject's exercise capacity.
  6. The subject is either treatment naïve or receiving an approved PDE-5 inhibitor and / or an approved ERA for at least 60 days prior to screening and is on a stable dose for 30 days and is willing to remain on a PDE-5 inhibitor and / or an ERA at the same dose for the duration of the 16-week treatment phase.
  7. The subject must be optimally treated with conventional pulmonary hypertension therapy (e.g., oral vasodilators, oxygen, digoxin, etc.) with no additions, discontinuations, or dose changes for at least 14 days prior to screening (excluding diuretics and anticoagulant dose adjustments).
  8. The subject has undergone right heart catheterisation at screening (or within 8 weeks before screening) and has been documented to have a mean pulmonary artery pressure (PAPm) of greater than or equal to 25 mmHg, a pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg, and pulmonary vascular resistance (PVR) of more than 3 Wood units.
  9. The subject has undergone echocardiography at screening with evidence of clinically normal left systolic and diastolic ventricular function, absence of any left sided heart disease (e.g., mitral valve stenosis) and absence of unrepaired congenital heart disease.
  10. The subject has a previous ventilation perfusion lung scan and / or high resolution computerised tomography scan of the chest and / or pulmonary angiography that is consistent with the diagnosis of PAH (e.g., low probability of pulmonary embolism; absence of major perfusion defects).
  11. The subject has pulmonary function tests done within 9 months of screening with the following:

    • Total lung capacity (TLC) was at least 60% (of predicted value)
    • /forced vital capacity (FEV1/FVC) ratio is at least 50%
  12. In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, was considered reliable, willing and likely to be cooperative with protocol requirements.
  13. The subject voluntarily gives written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. The subject has received epoprostenol, treprostinil, intravenous iloprost, or beraprost within 30 days prior to screening (except if used during acute vasoreactivity testing).
  3. The subject has had previous intolerance or significant lack of efficacy to prostacyclin or a prostacyclin analogue that resulted in discontinuation or inability to titrate that therapy effectively.
  4. The subject has any disease associated with PH other than idiopathic PAH or heritable PAH or had had an atrial septostomy.
  5. The subject is in WHO functional class IV.
  6. The subject has a current diagnosis of uncontrolled sleep apnoea as defined by their physician.
  7. The subject has liver function tests ( (AST) or alanine transaminase (ALT)) greater than three times the upper limit of the laboratory reference range and / or an (INR) greater than 3 units at screening.
  8. The subject has a history of active gastro-intestinal ulcer, intracranial haemorrhage, injury or other cause of bleeding episode within 6 months before screening, or has any other disease / condition that would either jeopardise the safety of the subject and / or interfere with the interpretation of study assessments in the opinion of the Investigator.
  9. The subject has a history of ischemic heart disease including previous myocardial infarction or symptomatic coronary artery disease within 6 months of screening, or history of left sided myocardial disease as evidenced by a PCWP (or Left Ventricular End-Diastolic Pressure (LVEDP)) greater than 15 mmHg or (LVEF) less than 40%.
  10. The subject has uncontrolled systemic hypertension as evidenced by systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.
  11. The subject has a musculoskeletal disorder (e.g., arthritis affecting the lower limbs, recent hip or knee joint replacement, artificial leg) or any other disease that is likely to limit ambulation, or is connected to a machine that is not portable.
  12. The subject has an unstable psychiatric condition or is mentally incapable of understanding the objectives, nature, or consequences of the trial.
  13. The subject is receiving an drug, has an investigational device in place or has participated in an investigational drug or device study within 30 days prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Remodulin

    Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.

    Drug: Remodulin

Interventions

  • Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.

    Also known as: Treprostinil

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Completion of the 16 Week Treatment Period.

    Successful completion was defined as completion of the 16 week treatment period of the study without experiencing any serious adverse events considered by the investigator to be possibly related to Remodulin.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Change From Baseline in Six Minute Walk Distance at Week 16.

    The purpose of the six minute walk test (6MWT) was to evaluate exercise capacity associated with carrying out activities of daily living. Patients were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes, resting whenever they needed. Distance \<500 meters suggests considerable exercise limitation; Distance 500 - 800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

    Time frame: Baseline to week 16

  2. Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 16

    The Borg dyspnea score is a 10 point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the 6MWT. The Borg dyspnea score was assessed immediately following the 6MWT. Scores range from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).

    Time frame: Baseline to week 16

  3. Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 16.

    The level of this biomarker of the (NT-proBNP) serum concentration was assessed to compare the severity of heart failure at Baseline and Week 16.

    Time frame: Baseline to week 16

  4. Number of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 16.

    The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

    Time frame: Baseline to week 16

  5. Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 16.

    The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning) and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, negative change scores indicate improvements.

    Time frame: Baseline to week 16

  6. Change From Baseline to Week 16 in Hemodynamic Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm).

    Pulmonary hypertension, an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by Swan-Ganz right heart catheterization. The PAPm, RAPm and PCWPm values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization and summarized.

    Time frame: Baseline to week 16

  7. Change From Baseline to Week 16 in Hemodynamic Parameters: Cardiac Index (CI) (L/Min/m^2)

    Cardiac Index (CI) relates the cardiac output (CO) to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization and summarized.

    Time frame: Baseline to week 16

  8. Change From Baseline to Week 16 in HemodynamicParameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)

    Pulmonary Vascular Resistance Index (PVRI) is calculated using Mean Pulmonary Arterial Pressure(PAPm), Pulmonary Capillary Wedge Pressure (PCWP) and Cardiac Index (CI ), to provide information about right ventricular load. The PVRI values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization.

    Time frame: Baseline to week 16

07

Results

Posted Sep 8, 2017

Participant flow

Participant flow — Overall Study
MilestoneRemodulin
Started39
Completed32
Not completed7
Withdrew: Adverse event3
Withdrew: Withdrawal by subject2
Withdrew: Clinical deterioration1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants With Successful Completion of the 16 Week Treatment Period.

Successful completion was defined as completion of the 16 week treatment period of the study without experiencing any serious adverse events considered by the investigator to be possibly related to Remodulin.

Time frame:
Baseline to week 16
Reported as:
Number · participants
Number of Participants With Successful Completion of the 16 Week Treatment Period.
participantsRemodulin
Number of Participants With Successful Completion of the 16 Week Treatment Period.32
SecondaryChange From Baseline in Six Minute Walk Distance at Week 16.

The purpose of the six minute walk test (6MWT) was to evaluate exercise capacity associated with carrying out activities of daily living. Patients were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes, resting whenever they needed. Distance \<500 meters suggests considerable exercise limitation; Distance 500 - 800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.

Time frame:
Baseline to week 16
Reported as:
Median · meters
Change From Baseline in Six Minute Walk Distance at Week 16.
metersRemodulin
Change From Baseline in Six Minute Walk Distance at Week 16.11.5 (-62 to 246)
SecondaryChange in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 16

The Borg dyspnea score is a 10 point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the 6MWT. The Borg dyspnea score was assessed immediately following the 6MWT. Scores range from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).

Time frame:
Baseline to week 16
Reported as:
Median · units on a scale
Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 16
units on a scaleRemodulin
Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 160.0 (-4 to 2)
SecondaryChange in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 16.

The level of this biomarker of the (NT-proBNP) serum concentration was assessed to compare the severity of heart failure at Baseline and Week 16.

Time frame:
Baseline to week 16
Reported as:
Median · pg/mL
Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 16.
pg/mLRemodulin
Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 16.-182.0 (-18396 to 9629)
SecondaryNumber of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 16.

The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

Time frame:
Baseline to week 16
Reported as:
Count of participants · Participants
Number of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 16.
ParticipantsRemodulin
II to II4
II to III1
III to II8
III to III18
III to IV1
SecondaryChange in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 16.

The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning) and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, negative change scores indicate improvements.

Time frame:
Baseline to week 16
Reported as:
Median · units on a scale
Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 16.
units on a scaleRemodulin
CAMPHOR total score-5.0 (-44 to 13)
Quality of life-1.0 (-13 to 7)
SecondaryChange From Baseline to Week 16 in Hemodynamic Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm).

Pulmonary hypertension, an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by Swan-Ganz right heart catheterization. The PAPm, RAPm and PCWPm values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization and summarized.

Time frame:
Baseline to week 16
Reported as:
Mean · mmHG
Change From Baseline to Week 16 in Hemodynamic Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm).
mmHGRemodulin
PAPm (mmHg)-3.2 ± 10.5
RAPm (mmHg)0.3 ± 5.6
PCWPm (mmHg)-0.3 ± 4.6
SecondaryChange From Baseline to Week 16 in Hemodynamic Parameters: Cardiac Index (CI) (L/Min/m^2)

Cardiac Index (CI) relates the cardiac output (CO) to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization and summarized.

Time frame:
Baseline to week 16
Reported as:
Mean · L/min/m^2
Change From Baseline to Week 16 in Hemodynamic Parameters: Cardiac Index (CI) (L/Min/m^2)
L/min/m^2Remodulin
Change From Baseline to Week 16 in Hemodynamic Parameters: Cardiac Index (CI) (L/Min/m^2)0.4 ± 0.4
SecondaryChange From Baseline to Week 16 in HemodynamicParameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)

Pulmonary Vascular Resistance Index (PVRI) is calculated using Mean Pulmonary Arterial Pressure(PAPm), Pulmonary Capillary Wedge Pressure (PCWP) and Cardiac Index (CI ), to provide information about right ventricular load. The PVRI values and their respective changes from Baseline to Week 16 were measured by SwanGanz right heart catheterization.

Time frame:
Baseline to week 16
Reported as:
Mean · mmHg*min*m^2/L
Change From Baseline to Week 16 in HemodynamicParameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)
mmHg*min*m^2/LRemodulin
Change From Baseline to Week 16 in HemodynamicParameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)-3.5 ± 4.5

Adverse events

Collected over Adverse events were recorded throughout the 16-week study, including the screening and follow-up phase, as well as 30 days post end of study visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remodulin0/39 (0%)11/39 (28.2%)39/39 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventRemodulin
Right Ventricular Failure (RVF)Cardiac disorders3/39
Fluid OverloadMetabolism and nutrition disorders2/39
Diarrhoea,Gastrointestinal disorders2/39
NauseaGastrointestinal disorders2/39
Infusion Site PainSkin and subcutaneous tissue disorders2/39
Rib FractureMusculoskeletal and connective tissue disorders1/39
HypotensionVascular disorders1/39
Atrial fibrillationCardiac disorders1/39
DyspnoeaRespiratory, thoracic and mediastinal disorders1/39
HeadacheNervous system disorders1/39
Most frequent other events
Showing 10 of 43
Most frequent other events
EventRemodulin
Infusion Site PainGeneral disorders36/39
DiarrhoeaGastrointestinal disorders28/39
HeadacheNervous system disorders27/39
NauseaGastrointestinal disorders18/39
VomitingGastrointestinal disorders15/39
Infusion Site ErythemaGeneral disorders10/39
Pain in jawMusculoskeletal and connective tissue disorders9/39
VertigoEar and labyrinth disorders8/39
DyspnoeaRespiratory, thoracic and mediastinal disorders8/39
Rheumatic disorderMusculoskeletal and connective tissue disorders7/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Remodulin
<=18 years0
Between 18 and 65 years29
>=65 years10
Age, Continuous
Age, Continuous(years)Remodulin
Median50 (25 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Remodulin
Female29
Male10
Region of Enrollment
Region of Enrollment(participants)Remodulin
Germany39
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Jul 28, 2016
Start
Apr 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Sep 8, 2017
Last update
Oct 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02847260
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Apr 2012
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Sep 8, 2017
Last update
Oct 17, 2017

Study contacts

Grünig
principal investigator · Thoraxklinik am Universitätsklinikum, Heidelberg, Germany
Klose
principal investigator · Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Rosenkranz
principal investigator · Universitätsklinikum Köln, Köln, Germany
Höffken
principal investigator · Universitaetsklinikum Dresden, Dresden, Germany
Lange
principal investigator · Universitätsklinikum Regensburg, Regensburg, Germany
Wirtz
principal investigator · Universitätsklinikum Leipzig, Leipzig, Germany
Neurohr
principal investigator · Klinikum Großhadern der LMU, Munich, Germany
Wilkens
principal investigator · Universitätsklinikum Klinik, Homburg, Germany
Held
principal investigator · Missionsärztliche Klinik, Würzburg, Germany
Krüger
principal investigator · Herzzentrum Duisburg, Duisburg, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion